• About
    • Company Profile
    • Company History
    • People
    • Privacy Policy
  • Clinical Need
  • Technology
    • Hu-PHEC
    • CDX Antibodies
    • HEMO-CAR-T
    • Advanced Hematopoietic Chimeras
  • Pipeline
  • Investors
    • Company Information & Prospectuses
      • Board of Directors
      • Corporate Governance
      • Corporate Advisers
      • Registrar & FAQs
    • Shareholder Information
    • Share Data & Announcements
    • Annual & Half Year Reports
    • Broker Coverage
    • Media Coverage
    • Videos & Presentations
  • News
  • Join Us
  • Contact

Broker Coverage

SP Angel

The most recent coverage is at the top; scroll down the page for prior coverage.

 

25 November 2021: updated coverage note for Hemogenyx Pharmaceuticals

SP Angel Hemogenyx Pharmaceuticals Update Note 20211125

 

23 July 2020: updated coverage note for Hemogenyx Pharmaceuticals

SP Angel Hemogenyx Update Note 20200723

 

29 August 2019: Initiation of coverage note for Hemogenyx Pharmaceuticals

SP Angel Hemogenyx Pharmaceuticals Initiation of Coverage Note 20190829

Loading

About Us

Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases

UK Headquarters

6th Floor, 60 Gracechurch Street, London, EC3V 0HR, United Kingdom

Research Facility

1361 Amsterdam Ave., Suite 320, New York, NY 10027, USA

Contact Us

© Hemogenyx Pharmaceuticals plc 2017--2023. All rights reserved. Hemogenyx Pharmaceuticals plc is registered in England and Wales as company number 08401609 at 6th Floor, 60 Gracechurch Street, London, EC3V 0HR, United Kingdom. LEI 2138008L93GYU5GN6179.
We set cookies on your computer by default to help make this website better. By continuing to use this site you are agreeing to our use of cookies. You can change your cookie settings at any time.
ACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT

SP Angel Research – Terms and Conditions

Access to SP Angel’s research via this web site is subject to the following terms and conditions. SP Angel (‘SPA’) does not deal with individual or private investors (save in connection with corporate finance business). SPA’s research is thus not prepared for private investors and does not take into account any particular investor’s or class of investors’ investment objectives. You are therefore not being granted access to SPA research in your capacity as an investor or SPA client or potential investor or client. You understand that SPA is not offering you any financial service. Members of SPA’s Research department are not permitted to interact with private investors and you should not attempt to contact them.